Recidivrisiko og varighed af antikoagulerende behandling efter dyb venøs trombose og lungeemboli
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Recidivrisiko og varighed af antikoagulerende behandling efter dyb venøs trombose og lungeemboli. / Comuth, Willemijn; Münster, Anna-Marie Bloch; Kümler, Thomas; Hellfritzsch, Maja; Larsen, Sanne Bøjet; Hansen, Morten Lock; Grove, Erik Lerkevang.
I: Ugeskrift for Laeger, Bind 181, V05180345, 2019.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Recidivrisiko og varighed af antikoagulerende behandling efter dyb venøs trombose og lungeemboli
AU - Comuth, Willemijn
AU - Münster, Anna-Marie Bloch
AU - Kümler, Thomas
AU - Hellfritzsch, Maja
AU - Larsen, Sanne Bøjet
AU - Hansen, Morten Lock
AU - Grove, Erik Lerkevang
PY - 2019
Y1 - 2019
N2 - If anticoagulant therapy is stopped, the risk of recurrence after unprovoked venous thromboembolism is high. After anticoagulant treatment for at least three months, the indication for prolonging therapy should be decided after thorough evaluation of individual risk factors for recurrence and bleeding. Clinical parameters, imaging modalities and D-dimer levels can guide this decision. The lower risk of bleeding on non-vitamin K-antagonist oral anticoagulants compared to warfarin is expected to increase the number of patients on extended treatment, but costs and patients' preferences should be considered.
AB - If anticoagulant therapy is stopped, the risk of recurrence after unprovoked venous thromboembolism is high. After anticoagulant treatment for at least three months, the indication for prolonging therapy should be decided after thorough evaluation of individual risk factors for recurrence and bleeding. Clinical parameters, imaging modalities and D-dimer levels can guide this decision. The lower risk of bleeding on non-vitamin K-antagonist oral anticoagulants compared to warfarin is expected to increase the number of patients on extended treatment, but costs and patients' preferences should be considered.
KW - Anticoagulants/therapeutic use
KW - Humans
KW - Pulmonary Embolism/drug therapy
KW - Recurrence
KW - Risk Factors
KW - Time Factors
KW - Venous Thromboembolism/complications
M3 - Tidsskriftartikel
C2 - 30777593
VL - 181
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
M1 - V05180345
ER -
ID: 241163647